Conclusions BCMA CAR T-cell therapy is teaching impressive results within an end-stage myeloma people, but relapses occur still
Conclusions BCMA CAR T-cell therapy is teaching impressive results within an end-stage myeloma people, but relapses occur still. for MM, with a particular focus on focus on selection, clinical outcomes, limitations, and potential strategies. = 4), 300 106 (= 70), and 450 106 (= 54). Entitled sufferers had three or even more preceding lines of…